Wednesday, November 23, 2016

Alzheimer's setback prompts rethink of Lilly, Biogen stock outlooks

NEW YORK, Nov 23 (Reuters) - Eli Lilly & Co's

massive setback for its experimental Alzheimer's disease

treatment on Wednesday sent investors scrambling to re-evaluate

shares of the U.S. drugmaker...

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)